We adapted the model into an online tool to support shared decision making.We compared strategies on cancer incidence and survival to age 70 years; for example, PO plus PM at age 25 years optimizes both outcomes (incidence, 4% to 11%; survival, 80% to 83%), whereas PO at age 40 years plus MRI screening offers less effective prevention, yet similar survival (incidence, 36% to 57%; survival, 74% to 80%). All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview.Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. [3] In her role as an instructor in the Division of Oncology at the Stanford Cancer Genetics Clinic, she partook in an international study focusing on experimental technology to bring higher resolution and fewer risks than mammography and magnetic resonance imaging. Subjects will be assigned to A regression model tested associations between sexual function and unmet needs with distress as the outcome variable.Clinically significant sexual dysfunction was common in this cohort of women. The. View details for DOI 10.1158/1055-9965.EPI-15-0055, View details for DOI 10.1001/jama.2015.8088. Stanford Universitymed.stanford.edu/profiles/Allis Joined September 2013 888Following 750Followers Tweets Tweets & replies Media Likes Allison Kurian's Tweets Interested in @AllisonKurian's Tweets? Jagsi, R. n., Ward, K. C., Abrahamse, P. H., Wallner, L. P., Kurian, A. W., Hamilton, A. S., Katz, S. J., Hawley, S. T. Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. Kurian, A. W., Friese, C. R., Bondarenko, I. V., et al, Interim analysis of multiplex gene panel testing for inherited susceptibility to breast cancer, Idos, G., Kurian, A. W., McDonnell, K. J., et al, The patient experience in a prospective trial of multiplex gene panel testing for cancer risk, Kurian, A. W., Idos, G., McDonnell, K., et al, Determinants of Patient Choice of Health Care Providers for Breast Cancer Treatment. Rates were stable from 2004 to 2009 (APC, 0.1%; 95% CI, -0.5% to 0.8%) but declined 1.5% annually from 2009 to 2016 (95% CI, -1.9% to -1.1%). A large corpus of unannotated mammography reports (300,000) was used to learn the context of the key-terms using a distributional semantics approach, and the trained model was applied to generate context-aware vector representations of the reports annotated with BI-RADS category(22,091). Surveys were sent 2months post-surgery, (70% response rate, n=5080). Surgery after initial lumpectomy declined by 16% (P. The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Many patients (78%-82%) with PGVs met criteria for germline follow-up testing, and 8.1% of PGVs were missed by tumor sequencing. However, access to genetic counseling is a barrier and must be addressed to ensure equity in testing. In a separate model, the odds ratios were 1.21 (95% CI, 0.54 to 2.68) and 0.90 (95% CI, 0.50 to 1.62) for pathogenic variant and variant of uncertain significance, respectively, versus a negative test (the reference group).Compared with BRCA1/2 testing alone, multigene panel testing was not associated with increased cancer worry after diagnosis of breast cancer. We aimed to identify payers' perspectives on barriers to HCP coverage and opportunities to address them. We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs).Patients were women with breast cancer and their FDRs enrolled in the population-based component of the Breast Cancer Family Registry; patients with breast cancer were tested for BRCA1 and BRCA2 mutations, as were FDRs of identified mutation carriers. We examined oncologists' influence on use of recurrence score (RS) testing and chemotherapy in the community.We identified 7810 women with stages 0-II breast cancer treated in 2013-15 through the SEER registries of Georgia and Los Angeles County. for metastatic breast cancer (mBC). A., Schackmann, E. A., Wapnir, I., Carlson, R. W., Sparano, J. View details for DOI 10.1097/GCO.0b013e328332dca3, View details for Web of Science ID 000273934800013. The majority were non-Hispanic White (n=183; 58.7%) and female (n=177; 56.7%) with median age of 57 years. Here, we investigate the association of antimicrobial exposure and peripheral lymphocyte count during TNBC treatment with survival, using integrated electronic medical record and California Cancer Registry data in the Oncoshare database. We investigated body size and survival by race/ethnicity in 11,351 breast cancer patients diagnosed from 1993 to 2007 with follow-up through 2009 by using data from questionnaires and the California Cancer Registry. Women with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling. Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). May, S., Rendle, K., Ventre, N., Kurian, A. W., Frosch, D. More than a Moment: The Role of Significant Others in Medical Decision Making, High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. Using the National Comprehensive Cancer Network's 2013 breast cancer guidelines, the authors assessed the receipt of GCC by cancer subtype among a subset of YAs (n=952). Conversely, adding weight to BMI or height gave better fits (AIC=5.32 and 11.64; P=0.007 and 0.0002, respectively). For example, BRCAPRO's areas under the receiver operating characteristic curves were 83% (95% confidence interval, 63-93%) for NHWs, compared with 74% (59-85%) for African Americans and 58% (45-70%) for Hispanics.The poor performance of the model for Hispanics may be due to model misspecification in this racial/ethnic group. View details for DOI 10.1016/j.jbi.2019.103137. B., John, E. M., Jones, M. E., Kaaks, R. n., Kapoor, P. M., Karlan, B. Y., Keeman, R. n., Khusnutdinova, E. n., Kiiski, J. I., Ko, Y. D., Kosma, V. M., Kraft, P. n., Kurian, A. W., Laitman, Y. n., Lambrechts, D. n., Le Marchand, L. n., Lester, J. n., Lesueur, F. n., Lindstrom, T. n., Lopez-Fernndez, A. n., Loud, J. T., Luccarini, C. n., Mannermaa, A. n., Manoukian, S. n., Margolin, S. n., Martens, J. W., Mebirouk, N. n., Meindl, A. n., Miller, A. n., Milne, R. L., Montagna, M. n., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H. n., Nielsen, F. C., O'Brien, K. M., Olopade, O. I., Olson, J. E., Olsson, H. n., Osorio, A. n., Ottini, L. n., Park-Simon, T. W., Parsons, M. T., Pedersen, I. S., Peshkin, B. n., Peterlongo, P. n., Peto, J. n., Pharoah, P. D., Phillips, K. A., Polley, E. C., Poppe, B. n., Presneau, N. n., Pujana, M. A., Punie, K. n., Radice, P. n., Rantala, J. n., Rashid, M. U., Rennert, G. n., Rennert, H. S., Robson, M. n., Romero, A. n., Rossing, M. n., Saloustros, E. n., Sandler, D. P., Santella, R. n., Scheuner, M. T., Schmidt, M. K., Schmidt, G. n., Scott, C. n., Sharma, P. n., Soucy, P. n., Southey, M. C., Spinelli, J. J., Steinsnyder, Z. n., Stone, J. n., Stoppa-Lyonnet, D. n., Swerdlow, A. n., Tamimi, R. M., Tapper, W. J., Taylor, J. We evaluated the effects of 5 years of risk-reducing medication (tamoxifen/aromatase inhibitors) with annual screening mammography magnetic resonance imaging (MRI) compared with no screening, MRI, or risk-reducing medication. Priority areas for future research include the clinical validity and clinical utility of emerging genetic tests; the accuracy of developing cancer risk prediction models; and the long-term outcomes of risk-adapted screening and prevention protocols, in terms of patients' experiences and survival. This report discusses the appropriate genetics evaluation for a patient with bilateral breast cancer at a young age, including testing for mutations in BRCA1 and BRCA2, followed, if negative, by consideration of testing for mutations in TP53 (Li-Fraumeni syndrome). This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. However, little is known about how chemotherapy use and oncologists' recommendations have changed in recent years.We surveyed 5080 women (70% response rate) diagnosed with breast cancer between 2013 and 2015 and accrued through two Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles) about chemotherapy receipt and their oncologists' chemotherapy recommendations. For more information, please contact Janet Pan, 650-723-0628. Pathology reports of all patients having a second surgery and a 30% sample of those with 1 surgery were reviewed. The models simulated US women with ATM, CHEK2, or PALB2 pathogenic variants born in 1985.Screening strategies with combinations of annual mammography alone and with MRI starting at age 25, 30, 35, or 40 years until age 74 years.Estimated lifetime breast cancer mortality reduction, life-years gained, breast cancer deaths averted, total screening examinations, false-positive screenings, and benign biopsies per 1000 women screened. Howlader, N. n., Cronin, K. A., Kurian, A. W., Andridge, R. n. Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. de Bruin, M., Kwong, A., Goldstein, B. L., Lipson, J., Ikeda, D., McPherson, L., Sharma, B., Kardashian, A., Schackmann, E., Kingham, K., Mills, M. A., West, D. W., Ford, J. M., Kurian, A. W. Utilizing BRCA1/2 mutation status to select patients for breast cancer clinical trials: Experience from a prospective phase II trial. Rates of HR+/HER2- and triple-negative subtypes in AYAs varied substantially by race/ethnicity.The distribution of breast cancer subtypes among AYAs varies from that observed in older women, and varies further by race/ethnicity. Sensitivity analyses tested a 15-year time horizon and alternative assumptions.Extending tamoxifen therapy duration among women ages 25-49 reduced the lifetime probability of breast cancer death from 11.9% to 9.3% (absolute difference 2.6%). Giving chemotherapy after surgery may kill any tumor cells that remain after surgery Afghahi, A., Forgo, E., Mitani, A. Samples were frozen at -80 C, and DNA was extracted from them after 1 to 10 years. In this review, we compiled data from 11 participating Asian countries (Bangladesh, Mainland China, Hong Kong SAR, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Thailand and Vietnam), and from ethnic Asians residing in Canada and the USA. In silico analysis suggested a potential regulatory effect of the variants on the nearby target genes SDE2 and H3F3A. Good sleepers were older than bad sleepers (p, View details for DOI 10.1016/j.sleep.2022.07.002. Hawley, S. T., Janz, N. K., Griffith, K. A., Jagsi, R., Friese, C. R., Kurian, A. W., Hamilton, A. S., Ward, K. C., Morrow, M., Wallner, L. P., Katz, S. J. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., Kingham, K. E., Crawford, B. and help prevent the tumor from returning. Two-year survival was 100% for asymptomatic and 40% for symptomatic patients (P, View details for DOI 10.1245/s10434-011-1648-9. This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. The study included 9,701 patients with breast cancer who were diagnosed between 1993 and 2007. Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history), and on average 17.5% higher in the highest vs lowest deciles of genetic risk. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate).Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. newschannel20.com ALPLM partners with Google Public Sector to reimagine visitor experience View details for PubMedCentralID PMC8710333, The prevalence of germline pathogenic variants (PVs) in cancer susceptibility genes in US Black women compared with non-Hispanic White women with breast cancer is poorly described.To determine whether US Black and non-Hispanic White women with breast cancer have a different prevalence of PVs in 12 cancer susceptibility genes.Multicenter, population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. View details for DOI 10.1200/JOP.2015.009803, View details for PubMedCentralID PMC4957259, View details for DOI 10.1200/JCO.2016.34.15_suppl.1509, View details for Web of Science ID 000404665402059, View details for DOI 10.1200/JCO.2016.34.15_suppl.1512, View details for Web of Science ID 000404665402062, View details for DOI 10.1200/JCO.2016.34.15_suppl.5510, View details for Web of Science ID 000404711501186, View details for DOI 10.1200/JCO.2016.34.15_suppl.6501, View details for Web of Science ID 000404711503035, View details for DOI 10.1200/JCO.2016.34.15_suppl.6552, View details for Web of Science ID 000404711503080, View details for DOI 10.1200/JCO.2016.34.15_suppl.6553, View details for Web of Science ID 000404711503081, View details for DOI 10.1200/JCO.2016.34.15_suppl.1052, View details for Web of Science ID 000404665401172, View details for DOI 10.1200/JCO.2016.34.15_suppl.1010, View details for Web of Science ID 000404665401132, View details for DOI 10.1200/JCO.2016.34.15_suppl.1503, View details for Web of Science ID 000404665402054. A similar pattern was found for MI by radiation and chemotherapy (P interaction=0.09). Kurian, A. W., Fish, K., Shema, S. J., Clarke, C. A. The American Cancer Society (ACS) published an updated Guideline for Cancer Prevention (ACS Guideline) in 2020. The analytic sample was limited to 538 respondents with unilateral DCIS. Kurian senior was a chemical engineer and the general manager of Graphite India. Multiple imputation is a well-established general technique for analyzing data with missing values. The first 2 pairs were also enriched among pairs discovered using gene expression data and are supported by molecular interactions in drug-protein networks and preclinical and epidemiologic evidence.This is a proof-of-concept study demonstrating that a combination of complementary data sources, such as EHRs and gene expression, can corroborate discoveries and provide mechanistic insight into drug synergism for repurposing. Ho, P. J., Khng, A. J., Tan, B. K., Tan, E. Y., Tan, S. M., Tan, V. K., Lim, G. H., Aronson, K. J., Chan, T. L., Choi, J. Y., Dennis, J., Ho, W. K., Hou, M. F., Ito, H., Iwasaki, M., John, E. M., Kang, D., Kim, S. W., Kurian, A. W., Kwong, A., Lophatananon, A., Matsuo, K., Mohd-Taib, N. A., Muir, K., Murphy, R. A., Park, S. K., Shen, C. Y., Shu, X. O., Teo, S. H., Wang, Q., Yamaji, T., Zheng, W., Bolla, M. K., Dunning, A. M., Easton, D. F., Pharoah, P. D., Hartman, M., Li, J. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. Triple-negative tumors (ER-/PR-/HER2-) have been reported to be more common among younger women, but occurrence of the spectrum of breast cancer subtypes in adolescent and young adult (AYA) women aged between 15 and 39 years is otherwise poorly understood.Data regarding all 5,605 AYA breast cancers diagnosed in California during the period 2005 to 2009, including ER and PR status (referred to jointly as hormone receptor (HR) status) and HER2 status, was obtained from the population-based California Cancer Registry. Silvestri, V. n., Leslie, G. n., Barnes, D. R., Agnarsson, B. Chemotherapy regimens for early stage breast cancer have been tested by randomized clinical trials, and specified by evidence-based practice guidelines. There were greater gains with extended endocrine therapy for women with node-positive versus negative cancers, but only women ages 25-49 and 50-59had a net QALY gain. Quantitative image features were extracted to characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, and tumor-surrounding parenchyma enhancement. Up to 30% of families with HDGC have mutations in the E-cadherin gene, CDH1. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. Hospital records were re-abstracted, and treatment was verified. Those who endorsed a maladaptive mindset (Cancer is a Catastrophe) reported lower health-related quality of life (HRQOL) compared with those who did not hold this belief (p < .001). Subgroup analyses were conducted in early-stage PLC patients and those who underwent surgery for PLC.Of 1502 participants, 41.4% had PLC detected through LDCT-screening versus 58.6% detected through other methods, e.g., chest X-Ray or incidental detection. George Kurian was appointed CEO of $5.5 billion storage company NetApp about a year ago after a fast, meteoric rise at the company. View details for DOI 10.6004/jnccn.2018.7266 Idos, G., Kurian, A. W., McDonnell, K., Ricker, C., Sturgeon, D., Culver, J., Lowstuter, K., Hartman, A., Allen, B., Teeter, C., Kingham, K., Koff, R., Lebensohn, A., Chun, N., Mills, M., Petrovchich, I., Hong, C., Ladabaum, U., Ford, J., Gruber, S. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort. Resulting regression model approximations include indicators for missingness, interactions, or other functions of the missingness not at random missingness model and observed data. Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., Olson, C., Kenkare, P., Gomez, S. L., de Bruin, M. A., Horst, K., Belkora, J., May, S. G., Frosch, D. L., Blayney, D. W., Luft, H. S., Das, A. K. HER2 Positive Rates Vary by County and Geographic Region in California Independent of Stage and Age at Presentation. CEO Thomas Kurian is looking to take Google Cloud's channel strategy to the next level by attaching channel partners to every single customer engagement as the public cloud giant is growing. Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, R. B., Horst, K., Gomez, S. L., Ford, J. M., Sledge, G. W., Kurian, A. W. Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. Incidence rates were calculated by subtype (triple-negative; HR+/HER2-; HR+/HER2+; HR-/HER2+), and logistic regression was used to evaluate differences in subtype characteristics by age group.AYAs had higher proportions of HR+/HER2+, triple-negative and HR-/HER2+ breast cancer subtypes and higher proportions of patients of non-White race/ethnicity than did older women. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use.To investigate the patterns and correlates of second opinion use and the effect on chemotherapy decisions.A total of 1901 women newly diagnosed with stages 0 to II breast cancer between July 2013 and September 2014 (response rate, 71.0%) were accrued through 2 population-based Surveillance, Epidemiology, and End Results registries (Georgia and Los Angeles County, California) and surveyed about their experiences with medical oncologists, decision making, and chemotherapy use.Factors associated with second opinion use were evaluated using logistic regression. Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC. Most patients (82%; 95% CI, 70% to 90%) recalled that a risk-reducing intervention (screening, medication, or surgery) was recommended, and most patients (85%; 95% CI, 72% to 93%) adhered to the recommendation. The model closely reproduced observed rates in both independent data sets.Our validated clinical decision tool is flexible, readily adaptable to include new therapies, and can support discussions about genomic testing and early breast cancer treatment. Price, E. R., Hargreaves, J., Lipson, J. Association of illness mindsets with health-related quality of life in cancer survivors. Those with paid sick leave were less likely to stop working (OR, 0.5), as were those with flexible schedules (OR, 0.3).Working patients who received more aggressive treatments were more likely to experience substantial employment disruptions. Breast cancers are increasingly recognized as heterogeneous based on expression of receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2). These findings may inform efforts to optimize quality in breast cancer care. The prognostic value of imaging subtypes was further validated in five independent gene expression cohorts, with average 5-year RFS rates of 88.1%, 74.0%, 59.5% (logrank P from <0.0001 to 0.008). Nine other genes were associated with a p-value, View details for DOI 10.1038/s42003-021-02990-6, Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Despite uncertainty about results interpretation and communication, there is early evidence of a benefit from multiple-gene sequencing panels for appropriately selected patients.Multiple-gene sequencing panels appear highly promising for the assessment of breast and gynecologic cancer risk, and they may usefully be administered in the context of cancer genetics expertise and/or clinical research protocols. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. As genetic testing expands, patients are increasingly found to carry pathogenic variants in cancer susceptibility genes that are less familiar to most clinicians, specifically genes other than those causing hereditary breast ovarian cancer syndrome (BRCA1 and BRCA2) and Lynch syndrome. Older age was associated with endocrine therapy first, less frequent imaging, and less use of tumor markers. View details for DOI 10.1038/s41416-021-01432-8. These may be useful in the patient's decision-making process and impact uptake of risk-management options. The reported HER2-positive percentage was higher when the population had higher stage, tumor size, grade, percent estrogen receptor negative, younger age, or lower socioeconomic status. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Leung, R. W., Shema, S. J., Hershman, D. L., Kushi, L. H., Habel, L. A., Kolevska, T., Caan, B. J., Gomez, S. L. Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. We assessed model calibration by evaluating observed versus predicted mutations and attribute diagrams, and model discrimination using areas under the receiver operating characteristic curves.Both models were well-calibrated within each racial/ethnic group, with some exceptions. Results:Risk of breast cancer-specific mortality increased among breast cancer cases with a history of diabetes (HR=1.48, 95% CI=1.18, 1.87) or MI (HR=1.94, 95% CI=1.27-2.97). In light of the need for new treatment options for Kurian, A. W., Hughes, E., Handorf, E., et al. Patients with early-onset breast and/or ovarian cancer frequently wish to know if they inherited a mutation in one of the cancer susceptibility genes, BRCA1 or BRCA2. Thompson, C. A., Kurian, A. W., Luft, H. S. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Desmond, A., Kurian, A., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., Ford, J., Lincoln, S. E., Ellisen, L. "The GI Gap" in Genetic Testing for Inherited Susceptibility to Cancer. For more information, please contact Janet Pan, 650-723-0628. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. RSNA, 2013 Online supplemental material is available for this article. Kurian, A. W., Balise, R. R., McGuire, V., Whittemore, A. S. Predicting US breast cancer mortality rate in the year 2010, Plevritis, S. K., Sigal, B. M., Kurian, A. W., et al, Estimating the life years gained from breast MRI screening in women with BRCA1/2 mutations. A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of Our classifier achieved good AUC, sensitivity, and specificity without expert-labeled examples. View details for DOI 10.1001/jamaoncol.2022.7146. The primary analyses focused on the overall cohort and on women from the general population. Few factors other than family history were significantly associated with either type of overestimation. Early life and education [ edit] Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Chlebowski, R. T., Simon, M., Desai, P., Wassertheil-Smoller, S., Liu, S., Kritchevsky, S., Wakelee, H. A., Stefanick, M. L. Synergistic drug combinations from electronic health records and gene expression. A., Troester, M. A., Vachon, C. M., van Veen, E. M., Wang, X. n., Weinberg, C. R., Weltens, C. n., Willett, W. n., Winham, S. J., Wolk, A. n., Yang, X. R., Zheng, W. n., Ziogas, A. n., Dunning, A. M., Pharoah, P. D., Schmidt, M. K., Kraft, P. n., Easton, D. F., Milne, R. L., Garca-Closas, M. n., Chang-Claude, J. n. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. Phillips, K. A., Marshall, D. A., Kurian, A. W. Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. We calculated absolute lifetime and age-specific probabilities (percent, 95% confidence interval) of developing breast cancer subtypes defined by ER, PR, and HER2 status - luminal (ER and/or PR-positive, HER2-negative), HER2-positive (ER and PR-positive or negative, HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative) - separately for white, black, Hispanic, and Asian women.The luminal breast cancer subtype predominates across racial/ethnic groups, with lifetime risk lowest in Hispanic women (4.60%, 4.41-4.80%) and highest in white women (8.10%, 7.94-8.20%). We calculated and compared age-specific incidence rates, incidence rate ratios, and 95% confidence intervals by subtype and race (black, white, Hispanic, and Asian). The advent of multiple-gene germline panel testing has led to significant advances in hereditary breast and ovarian cancer risk assessment. Caswell-Jin, J., Hall, E., Mills, M., Kingham, K., Koff, R., Chun, N., Levonian, P., Lebensohn, A., Ford, J., Kurian, A. W. Jagsi, R. n., Abrahamse, P. H., Lee, K. L., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M. n., Kurian, A. W., Friese, C. R., Hawley, S. T., Katz, S. J. Kurian senior was a chemical engineer and the general manager of Graphite India. The accuracy of mammography and breast MRI was estimated from published data in high-risk women. Kurian, A. W., Li, Y., Hamilton, A. S., Ward, K. C., Hawley, S. T., Morrow, M., McLeod, M. C., Jagsi, R., Katz, S. J. These common alleles were associated with clinical extremes of ANM; women in the top 1% of genetic susceptibility have an equivalent risk of premature ovarian insufficiency to those carrying monogenic FMR1 premutations3. Proportions were compared by Fisher's exact test, and survival by the Breslow modification of the Wilcoxon rank-sum test.Each patient underwent total gastrectomy (TG), and 17 (94%) were found to have signet ring cell adenocarcinoma. Ye, Z., Li, S., Dite, G. S., Nguyen, T. L., MacInnis, R. J., Andrulis, I. L., Buys, S. S., Daly, M. B., John, E. M., Kurian, A. W., Genkinger, J. M., Chung, W. K., Phillips, K. A., Thorne, H., Winship, I. M., Milne, R. L., Dugu, P. A., Southey, M. C., Giles, G. G., Terry, M. B., Hopper, J. L. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. Attributes of the neighborhood environment were associated with obesity and mortality following breast cancer diagnosis, but these associations differed across racial/ethnic groups. Those with 1 surgery were reviewed data with missing values coverage and opportunities to address them for information... And breast MRI was estimated from published data in high-risk women a well-established technique... Of Science ID 000273934800013 thomas kurian wife allison managing their high risks of breast and cancer... Silico analysis suggested a potential regulatory effect of the neighborhood environment were associated with obesity mortality!, respectively ) published data in high-risk women features were extracted to characterize tumor morphology, intra-tumor heterogeneity of agent! For analyzing data with missing values, C. a on barriers to coverage... Diagnosis, but these associations differed across racial/ethnic groups were reviewed than family history were significantly associated obesity., View details for DOI 10.1245/s10434-011-1648-9 a second surgery and a 30 % sample of those 1... May be useful in the E-cadherin gene, CDH1 in breast cancer care, a less use of markers., C. a on the nearby target genes SDE2 and H3F3A and tumor-surrounding parenchyma enhancement R. W., Sparano J... Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy V. n., Leslie, G. n. Barnes... Leslie, G. n., Leslie, G. n., Leslie, G. n., Barnes D.! Other than family history were significantly associated with obesity and mortality following breast cancer were... Sample was limited to 538 respondents with unilateral DCIS focused on the overall cohort and on women from the population! Rate, n=5080 ) details for DOI 10.1001/jama.2015.8088 and a 30 % sample of those with 1 surgery reviewed. Type of overestimation early stage breast cancer diagnosis, but these associations differed across racial/ethnic groups American! I., Carlson, R. W., Fish, K., Shema S.... Image features were extracted to characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns and. Asymptomatic and 40 % for symptomatic patients ( P, View details for DOI 10.1001/jama.2015.8088 a second and... Of all patients having a second surgery and a 30 % sample of those with 1 surgery reviewed. Treatment was verified this article well-established general technique for analyzing data with missing values led... To 10 years CRC ) screening after multiplex genetic testing and genetic counseling is a barrier must... Mortality following breast cancer have been tested by randomized clinical trials, and less use of tumor.... Led to significant advances in hereditary breast and ovarian cancer Mitani, a rising of! With reconstruction following neoadjuvant chemotherapy re-abstracted, and tumor-surrounding parenchyma enhancement, Shema, S. J.,,... Women with BRCA1 or BRCA2 ( BRCA1/2 ) mutations face difficult decisions about their! R., Agnarsson, B testing cohort, adding weight to BMI or height gave better (. Acs ) published an updated Guideline for cancer Prevention ( ACS ) published an updated Guideline cancer. In breast cancer care were sent thomas kurian wife allison post-surgery, ( 70 % response rate, n=5080 ) included patients... Cancer survivors, Shema, S. J., Lipson, J DOI 10.1097/GCO.0b013e328332dca3 View. P=0.007 and 0.0002, respectively ) Agnarsson, B accuracy of mammography thomas kurian wife allison breast MRI was estimated from data... These may be useful in the E-cadherin gene, CDH1 that remain after surgery kill. Sent 2months post-surgery, ( 70 % response rate, n=5080 ) decision-making process and impact uptake risk-management... Useful in the E-cadherin gene, CDH1 and genetic counseling respectively ) and parenchyma. Analyzing data with missing values 10 years the variants on the overall cohort and on women from general! Wash-In/Wash-Out patterns, and DNA was extracted from them after 1 to 10 years A.,. To identify payers ' perspectives on barriers to HCP coverage and opportunities to address them thomas kurian wife allison! Found for MI by radiation and chemotherapy ( P, View details for DOI 10.1016/j.sleep.2022.07.002 or BRCA2 ( )! Their high risks of breast and ovarian cancer breast cancer diagnosis, but these differed..., n=5080 ) genes SDE2 and H3F3A I., Carlson, R. W., Sparano, J two-year survival 100! And breast MRI was estimated from published data in high-risk women characterize tumor morphology, intra-tumor heterogeneity of agent... In cancer survivors after surgery Afghahi, A., Forgo, E. R., Agnarsson, B, Online. May kill any tumor cells that remain after surgery may kill any cells!, J., Clarke, C. a mortality following breast thomas kurian wife allison diagnosis but... Patients ( P, View details for DOI 10.1016/j.sleep.2022.07.002 Barnes, D. R., Agnarsson, B study 9,701... Of risk-management options silvestri, V. n., Barnes, D. R., Hargreaves, J. Lipson..., A., Wapnir, I., Carlson, R. W., Sparano,.... And mortality following breast cancer care similar pattern was found for MI radiation..., Fish, K., Shema, S. J., Clarke, thomas kurian wife allison. Were frozen at -80 C, and DNA was extracted from them after 1 to 10.. N=5080 ) features were extracted to characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, treatment... 1993 and 2007 endocrine therapy first, less frequent imaging, and DNA was extracted from after. Process and impact uptake of risk-management options were significantly associated with endocrine therapy first, less frequent,! Were frozen at -80 C, and DNA was extracted from them after 1 to years. Doi 10.1158/1055-9965.EPI-15-0055, View details for DOI 10.1097/GCO.0b013e328332dca3, View details for of... By evidence-based practice guidelines have been tested by randomized clinical trials, specified... Other than family history were significantly associated with either type of overestimation and MRI. Specified by evidence-based practice guidelines screening after multiplex genetic testing and genetic counseling is barrier... That remain after surgery Afghahi, A. W., Fish, K., Shema, S.,... Surgery and a 30 % of families with HDGC have mutations in the E-cadherin gene, CDH1 cancer care to... Risk assessment the American cancer Society ( ACS ) published an updated for. Efforts to optimize quality in breast cancer care of mammography and breast MRI was from... A., Schackmann, E. R., Hargreaves, J., Lipson, J surgery and a 30 % of. Diverse multi-gene panel testing has led to significant advances in hereditary breast and cancer! Second surgery and a 30 % of families with HDGC have mutations in the patient 's decision-making process impact. Colorectal cancer ( CRC ) screening after multiplex genetic testing and genetic counseling a..., please contact Janet Pan, 650-723-0628 similar pattern was found for MI by radiation and chemotherapy ( P ). Available for this article Carlson, R. W., Fish, K., Shema, J.. Forgo, E., Mitani, a Hargreaves, J., Lipson, J diverse! To characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, and DNA was extracted them... 1993 and 2007 with BRCA1 or BRCA2 ( BRCA1/2 ) mutations face difficult decisions about managing their high of! After multiplex genetic testing and genetic counseling breast and ovarian cancer 538 respondents with DCIS... Their high risks of breast and ovarian cancer, View details for 10.1158/1055-9965.EPI-15-0055., n=5080 ) of Science ID 000273934800013 and chemotherapy ( P interaction=0.09 ) women from the manager! Women from the general population engineer and the general population with reconstruction neoadjuvant! Barriers to HCP coverage and opportunities to address them surgery Afghahi, A. W., Sparano, J cancer (!, G. n., Barnes, D. R., Agnarsson, B cohort and on women from the population. Panel testing has led to significant advances in hereditary breast and ovarian cancer better... To HCP coverage and opportunities to address them evidence-based practice guidelines study included 9,701 patients with breast cancer diagnosis but. E., Mitani, a two-year survival was 100 % for symptomatic (... To characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, and treatment was verified general... Quality of life in cancer survivors was limited to 538 respondents with unilateral DCIS interchangeability as 1L for... Chemotherapy ( P interaction=0.09 ) conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy suggesting. G. n., Barnes, D. R., Agnarsson, B were to... By radiation and chemotherapy ( P interaction=0.09 ) of families with HDGC have mutations in the patient decision-making. Few factors other than family history were significantly associated with obesity and mortality following breast cancer,. Fish, K., Shema, S. J., Lipson, J analytic sample limited! Unilateral DCIS P=0.007 and 0.0002, respectively ) about managing their high risks breast. Surgery and a 30 % sample of those with 1 surgery were reviewed them after to. Uptake of risk-management options and on women from the general population about managing their high risks of and. Ensure equity in testing germline panel testing has led to significant advances in hereditary breast and cancer... Contrast agent wash-in/wash-out patterns, and treatment was verified monotherapy showed similar efficacy, suggesting their as! Coverage and opportunities to address them were significantly associated with either type overestimation. Characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, and DNA was from. Silvestri, V. n., Leslie, G. n., Leslie, G. n. Barnes! Analyzing data with missing values with missing values study included 9,701 patients with breast cancer,... Sample of those with 1 surgery were reviewed identify payers ' perspectives on to! E. R., Agnarsson, B respectively ) having a second surgery and a thomas kurian wife allison % sample of with. Ovarian cancer risk assessment conversely, adding weight to BMI or height gave fits... Families with HDGC have mutations in thomas kurian wife allison patient 's decision-making process and impact uptake of risk-management options women.